HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells

Keyphrases

• Bortezomib 100%
• Human Pancreatic Cancer Cells 100%
• Translational Repression 100%
• Proteotoxicity 100%
• Heme-regulated Inhibitor 100%
• Phosphorylation 25%
• Protein Aggregates 25%
• EIF2α Phosphorylation 25%
• EIF2 25%
• EIF2α Kinase 25%
• Molecular Mechanism 12%
• Cell Surface Display 12%
• Cell Death 12%
• Reactive Oxygen Species 12%
• Cancer Cells 12%
• Knockdown 12%
• Novel Therapeutic Targets 12%
• Resistant Cell Lines 12%
• Resistant Cells 12%
• Strategies to Overcome 12%
• Translation Inhibition 12%
• Human Pancreatic Cancer Cell Line 12%
• Velcade 12%
• Proteasome Inhibitor Resistance 12%
• Overcoming Resistance 12%
• Reactive Oxygen Species Generation 12%
• Proteasome Inhibitor Bortezomib 12%

Immunology and Microbiology

• Cancer Cell 100%
• Initiation Factor 2 100%
• Heme 100%
• phosphorylation 66%
• Proteasome 33%
• Kinase 33%
• Phosphotransferase 33%
• Dioxygen 33%
• Cell Line 16%
• Cell Death 16%
• Pancreatic Cancer Cell Line 16%
• Bortezomib-Resistant Cell Line 16%
• Therapeutic Target 16%

Biochemistry, Genetics and Molecular Biology

• Cancer Cell 100%
• Proteotoxicity 100%
• phosphorylation 100%
• Kinase 50%
• Phosphotransferase 50%
• Proteasome Inhibitor 50%
• Cell Death 25%
• Molecular Mechanism 25%